v3.26.1
Business segment information (Tables)
6 Months Ended
Jun. 27, 2026
Business segment information  
Segment revenue reconciles to statutory revenues from continuing operations

​

​

​

​

​

​

​

  ​ ​ ​

27 June

  ​ ​ ​

28 June

​

​

2026

​

2025

​

​

$m

​

$m

Reportable segment revenue

 

  ​

 

  ​

Sports Medicine & ENT

​

1,017

​

923

Advanced Wound Management

​

867

​

845

Orthopaedics

​

1,213

​

1,193

Revenue from external customers

​

3,097

​

2,961

Disaggregation of revenue

​

​

​

​

​

​

​

  ​ ​ ​

27 June

  ​ ​ ​

28 June

Revenue by product from continuing operations

​

2026

​

2025

​

​

$m 

​

$m 

Sports Medicine Joint Repair

 

574

 

509

Arthroscopic Enabling Technologies

 

340

 

307

ENT (Ear, Nose and Throat)

​

103

 

107

Sports Medicine & ENT

 

1,017

 

923

Advanced Wound Care

 

398

 

366

Advanced Wound Bioactives

 

263

 

285

Advanced Wound Devices

 

206

 

194

Advanced Wound Management

 

867

 

845

Knee Implants

 

492

 

501

Hip Implants

 

326

 

313

Other Reconstruction

 

68

 

64

Trauma & Extremities

 

327

 

315

Orthopaedics

 

1,213

 

1,193

Total

 

3,097

 

2,961

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

27 June 2026

​

28 June 2025

​

​

Established
MarketsE

​

Emerging
Markets

​

Total

​

Established
MarketsE

​

Emerging
Markets

​

Total

​

  ​ ​ ​

$m 

  ​ ​ ​

$m 

  ​ ​ ​

$m 

  ​ ​ ​

$m 

  ​ ​ ​

$m 

  ​ ​ ​

$m 

Orthopaedics, Sports Medicine & ENT

​

1,810

​

420

​

2,230

​

1,752

​

364

​

2,116

Advanced Wound Management

​

739

​

128

​

867

​

731

​

114

​

845

Total

​

2,549

 

548

​

3,097

​

2,483

 

478

​

2,961

E

Established Markets comprises US, Australia, Canada, Europe, Japan and New Zealand.

Trading profit reconciles to operating profit

​

​

​

​

​

​

​

​

27 June

​

28 June

​

​

2026

​

2025

​

  ​ ​ ​

$m

  ​ ​ ​

$m

Segment profit

​

​

​

​

Sports Medicine & ENT

 

251

​

213

Advanced Wound Management

 

191

​

187

Orthopaedics

 

158

​

151

Segment trading profit

 

600

​

551

Corporate costs1

​

(34)

​

(28)

Acquisition and disposal related items

​

(21)

​

(9)

Restructuring and rationalisation expenses

​

(23)

​

(8)

Amortisation and impairment of acquisition intangibles

​

(87)

​

(83)

Legal and other

 

13

​

6

Operating profit

 

448

​

429

Interest income

​

10

​

15

Interest expense

​

(65)

​

(69)

Other finance costs

​

(18)

​

(12)

Share of results of associates

​

5

​

(1)

Profit before taxation

​

380

​

362

1

Corporate costs include centralised infrastructure costs such as compliance and group functions.

Schedule of depreciation and amortisation included in segment profit

​

​

​

​

​

​

​

​

27 June

​

28 June

​

​

2026

​

2025

​

  ​ ​ ​

$m

  ​ ​ ​

$m

Depreciation and amortisation

​

​

​

​

Sports Medicine & ENT

​

55

​

51

Advanced Wound Management

​

37

​

34

Orthopaedics

​

115

​

112